Olema Pharmaceuticals, Inc.OLMANASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-9.00%
↓ 139% below average
Average (23q)
23.21%
Historical baseline
Range
High:144.91%
Low:-34.85%
Volatility
774.6%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -9.00% |
| Q2 2025 | 43.36% |
| Q1 2025 | -5.19% |
| Q4 2024 | -2.79% |
| Q3 2024 | 14.14% |
| Q2 2024 | -2.59% |
| Q1 2024 | 15.50% |
| Q4 2023 | 33.00% |
| Q3 2023 | 8.14% |
| Q2 2023 | -21.19% |
| Q1 2023 | 5.75% |
| Q4 2022 | 22.45% |
| Q3 2022 | -34.85% |
| Q2 2022 | 68.99% |
| Q1 2022 | 0.21% |
| Q4 2021 | 27.57% |
| Q3 2021 | 5.15% |
| Q2 2021 | 11.39% |
| Q1 2021 | 70.01% |
| Q4 2020 | 34.58% |
| Q3 2020 | 140.01% |
| Q2 2020 | 144.91% |
| Q1 2020 | -12.64% |
| Q4 2019 | 0.00% |